Publicacións en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (28)

2024

  1. Neddylation orchestrates the complex transcriptional and posttranscriptional program that drives Schwann cell myelination

    Science Advances, Vol. 10, Núm. 15

2023

  1. Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression

    Hepatology, Vol. 77, Núm. 5, pp. 1654-1669

  2. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

    Cell Metabolism, Vol. 35, Núm. 8, pp. 1373-1389.e8

  3. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

    Journal of Hepatology, Vol. 76, Núm. 1, pp. 11-24

  2. Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

    Nature Communications, Vol. 13, Núm. 1

  3. Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals

    Hepatology, Vol. 75, Núm. 3, pp. 550-566

2021

  1. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  2. Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

    Journal of Hepatology, Vol. 75, Núm. 1, pp. 34-45

  3. The L-α-Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis

    Hepatology, Vol. 73, Núm. 2, pp. 606-624

2020

  1. HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis

    The Journal of clinical investigation, Vol. 130, Núm. 7, pp. 3848-3864

  2. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

    Nature Communications, Vol. 11, Núm. 1

  3. Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly

    Cell Metabolism, Vol. 31, Núm. 3, pp. 605-622.e10

2019

  1. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer

    EBioMedicine, Vol. 40, pp. 406-421

  2. miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease

    Molecular Metabolism, Vol. 29, pp. 40-54

2017

  1. Deregulated neddylation in liver fibrosis

    Hepatology, Vol. 65, Núm. 2, pp. 694-709

  2. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis

    Gastroenterology, Vol. 152, Núm. 6, pp. 1449-1461.e7

  3. Role of aramchol in steatohepatitis and fibrosis in mice

    Hepatology Communications, Vol. 1, Núm. 9, pp. 911-927

2016

  1. Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis

    Journal of Hepatology, Vol. 64, Núm. 2, pp. 409-418

  2. Stratification and therapeutic potential of PML in metastatic breast cancer

    Nature Communications, Vol. 7